PartnerFacts
Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 10:34 AM ET

Sponsor Check › Person

AX
No photo found yet (own website and image search run after this page is viewed)

Asish Xavier

Named as an officer, director or promoter on SEC Form D filings · CA, NJ, British Columbia, Canada (as filed: A1), MA, PA, NY, WA · Dec 8, 2008 → Jun 11, 2024

22deals (issuers)
$990.9Mreported sold
435investors
66Form D filings
2008–2024years on file
Follow this personLook further ↓PDF

Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:17 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET

The short version

Asish Xavier is listed as a director on 66 SEC Form D filings by 22 issuers between Dec 2008 and Jun 2024. Largest by amount reported sold: ImmPACT Bio USA Inc. (West Hills, CA — biotechnology — 2020; $139.9M reported sold to 17 investors), SonoThera, Inc. (South San Francisco, CA — biotechnology — 2022; $125.5M reported sold to 22 investors), Bright Peak Therapeutics, Inc. (Del Mar, CA — industry reported as "Other" — 2024; $106.5M reported sold to 21 investors), Adicet Bio, Inc. (Menlo Park, CA — biotechnology — 2019; $80M reported sold to 18 investors), GENOCEA BIOSCIENCES, INC. (Cambridge, MA — biotechnology — 2012–2013; $75.5M reported sold to 21 investors) and 17 more (all listed below).

What this means That is a lot of deals — 22 separate companies raised money with this person listed as director, over about 16 years. Across those companies the filings report $990.9M sold in total.

Listed alongside Steve Gillis (13 shared filings), Thong Le (13 shared filings), Joel S. Marcus (11 shared filings), David Schubert (10 shared filings), Andrew E. Senyei (8 shared filings) and 186 others.

What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Asish. Each name links to their own page.

The issuers belong to 2 sponsor groups: Aquinox Pharmaceuticals (2 issuers, $14M reported sold, 2010–2013) and Eiger Biopharmaceuticals (2 issuers, $9M reported sold, 2009–2016).

What this means This person is listed across more than one sponsor team; each group page shows that team's full track record.

Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CO, CT, DC, DE, FINRA, FL, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, WA, WI, WV, WY) — none found.

What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.

We compared the newest 50 of 66 public filings for Asish Xavier and found 15 differences, 6 worth asking the sponsor about: Investor count went down between filings; Asish Xavier appears on 3 deals that stopped filing before reaching their target; and more below.

What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.

What the community is saying

Community search for Asish Xavier has not run yet — it is joining a line of 56,708 names; searches run around the clock at the hosts' allowed rate. Searched so far: 641 names.

Community comments are quoted as written by their authors. Sources searched: Bing (site:reddit.com / site:biggerpockets.com) and Reddit's own search, plus DuckDuckGo/Brave/BiggerPockets search when they are answering.

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

None found in sources searched — federal courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:17 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: 48 regulators (FINRA, NASAA, 37 states) — crawled Oct 24, 2026, 8:48 AM ET

What was searched

SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched Asish Xavier..

State securities regulators: Securities regulators searched (64,910 actions): FINRA (38,350 actions, 1995–2026), NASAA (31 actions, 2000–2026; listing starts 1997), AK Division of Banking and Securities (273 actions, 1971–2025), AL Securities Commission (880 actions, 2001–2026), AR Securities Department (1,305 actions, 1998–2026), AZ Corporation Commission Securities Division (411 actions, 2017–2026), CA DFPI (25 actions, 2007–2024; listing starts 2002 — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), CO Division of Securities (731 actions, 2001–2026; older years from the Internet Archive (snapshot of 2026-05-02)), CT Department of Banking Securities Division (940 actions, 2006–2026; older years from the Internet Archive (snapshot of 2026-04-22)), DC DISB Securities Bureau (25 actions, 2012–2026), DE DOJ Investor Protection Unit (257 actions, 1987–2026), FL Office of Financial Regulation (49 actions, 2018–2026), GA Secretary of State Securities Division (65 actions, 2015–2026; listing starts 2012), HI DCCA Securities Enforcement Branch (26 actions, 2012–2026), ID Department of Finance Securities Bureau (663 actions, 1994–2026), IL Secretary of State Securities Department (4,122 actions, 2003–2023), KS Insurance Department Securities Division (58 actions), KY Department of Financial Institutions (342 actions, 2005–2026), LA Office of Financial Institutions Securities Division (13 actions, 2010–2025; listing starts 2008), MA Secretary of the Commonwealth Securities Division (125 actions, 2012–2025; live site blocks automated access — loaded from the Internet Archive snapshot of 2026-02-04), MD Attorney General Securities Division (1,054 actions, 2004–2026), ME Office of Securities (539 actions, 2000–2026), MI LARA Corporations, Securities & Commercial Licensing Bureau (201 actions), MO Secretary of State Securities Division (919 actions, 1998–2026), MS Secretary of State Securities Division (209 actions, 1995–2026), MT Commissioner of Securities and Insurance (597 actions, 2000–2026), NC Secretary of State Securities Division (265 actions, 2004–2024), ND Securities Department (711 actions, 1990–2026; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2026-01-06), NH Bureau of Securities Regulation (402 actions, 2002–2026), NM Regulation and Licensing Department Securities Division (90 actions, 2010–2025), NV Secretary of State Securities Division (118 actions, 2018–2026), NY Attorney General Investor Protection Bureau (44 actions, 2012–2026), OH Division of Securities (327 actions, 1993–2006), OK Department of Securities (2,531 actions, 1998–2026), OR Division of Financial Regulation (589 actions, 1988–2026), PA Department of Banking and Securities (1,448 actions, 2008–2024; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2024-08-09), RI DBR Securities Division (98 actions, 2005–2025), SC Attorney General Securities Division (540 actions, 2006–2026), SD Division of Insurance – Securities Regulation (106 actions, 2017–2026), TN Department of Commerce and Insurance Securities Division (405 actions, 1992–2026), TX State Securities Board (936 actions, 1999–2026), UT Division of Securities (772 actions, 2000–2026; older years from the Internet Archive (snapshot of 2010-05-27)), VT DFR Securities Division (137 actions, 2010–2026), WA DFI (2,039 actions, 2001–2026), WI DFI Division of Securities (1,072 actions, 1998–2026), WV Securities Commission (State Auditor) (64 actions), WY Secretary of State Compliance Division (6 actions, 2016–2024) — last crawled Oct 24, 2026, 8:48 AM ET. No machine-readable public listing today for IA, IN, MN, NE, NJ, VA (see docs/state-regulators.md).

3. Bankruptcies

None found in sources searched — federal bankruptcy courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:17 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

4. Differences between public sources

Comparisons cover issuers and sponsor groups — see the issuer pages under Deals

15 differences found between the filings for Asish Xavier — 6 worth asking about (compared the newest 50 of 66 filings on Oct 24, 2026; older filings not covered)

Note · Apr 15, 1991 – Nov 25, 2024

6 bankruptcy cases name the subject or team members

Bankruptcy case: Genocea Biosciences, Inc. — filed Jul 5, 2022 · Bankruptcy case: Genocea Biosciences, Inc. v. 100 Discovery Park DE, LLC — filed Jan 26, 2023 · Bankruptcy case: Moldt v. US Bank NA — filed Jun 12, 2013 · Bankruptcy case: Michael L. Gutch — filed Dec 16, 2011 · Bankruptcy case: WELLS FARGO BANK, N.A. v. Shanafelt — filed Apr 3, 2008 · and 1 more

What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.

Docket · United States Bankruptcy Court, D. Massachusetts ↗GENOCEA BIOSCIENCES, INC. — PartnerFacts page ↗Docket · United States Bankruptcy Court, D. Massachusetts ↗Docket · United States Bankruptcy Court, W.D. Washington ↗
Sources
Worth asking · Jun 2, 2017 – Oct 11, 2018

Investor count went down between filings — ESCAPE Bio, Inc.

The Jun 2, 2017 filing reports 32 investors; the Oct 11, 2018 Form D/A reports 31 investors.

What this means Investor counts normally only grow. A smaller number can mean investors left or were refunded, or a count was corrected. Ask the sponsor what happened.

Form D/A (earlier) · Jun 2, 2017 ↗Form D/A (later) · Oct 11, 2018 ↗ESCAPE Bio, Inc. — PartnerFacts page ↗
Sources
Worth asking · Jan 6, 2016 – Jan 4, 2017

Investor count went down between filings — Petra Pharma Corp

The Jan 6, 2016 filing reports 12 investors; the Jan 4, 2017 Form D/A reports 11 investors.

What this means Investor counts normally only grow. A smaller number can mean investors left or were refunded, or a count was corrected. Ask the sponsor what happened.

Form D (earlier) · Jan 6, 2016 ↗Form D/A (later) · Jan 4, 2017 ↗Petra Pharma Corp — PartnerFacts page ↗
Sources
Worth asking · Jul 24, 2015 – Feb 11, 2019

Asish Xavier appears on 3 deals that stopped filing before reaching their target

Aldeyra Therapeutics, Inc. (last filing Feb 11, 2019; $10,000,000 sold of $25,000,000); Eiger BioPharmaceuticals, Inc. (last filing Apr 29, 2016; $21,800,002 sold of $64,537,095); Protagonist Therapeutics, Inc (last filing Jul 24, 2015; $17,499,999 sold of $40,000,000). Each has no filing in more than two years and reported under half its target sold.

What this means An issuer whose last filing is more than two years old and reported under half its target sold. The raise may have closed early or quietly stopped. Ask what happened to each.

Aldeyra Therapeutics, Inc. — PartnerFacts page ↗Eiger BioPharmaceuticals, Inc. — PartnerFacts page ↗Protagonist Therapeutics, Inc — PartnerFacts page ↗
Sources
Worth asking · Jul 29, 2011 – Jun 11, 2024

8 Form Ds were filed more than 15 days after the first sale

Form D filed 244 days after the first sale — SonoThera, Inc. · Form D filed 76 days after the first sale — Adicet Bio, Inc. · Form D filed 35 days after the first sale — Bright Peak Therapeutics, Inc. · Form D filed 16 days after the first sale — ViaCyte Inc. · Form D filed 20 days after the first sale — ImmPACT Bio USA Inc. · and 3 more

What this means Late notices are common and carry no penalty by themselves. A pattern of late paperwork is worth asking the sponsor about.

Form D · Dec 29, 2022 ↗SonoThera, Inc. — PartnerFacts page ↗Form D · Oct 9, 2019 ↗Adicet Bio, Inc. — PartnerFacts page ↗
Sources
Note · Nov 8, 2011 – Mar 17, 2023

22 offerings have no amendment in the last 12 months and may still be open

No amendment in the last 12 months on an offering that may still be open — PAIGE.AI, Inc. (latest filing Mar 17, 2023) · No amendment in the last 12 months on an offering that may still be open — SonoThera, Inc. (latest filing Dec 29, 2022) · No amendment in the last 12 months on an offering that may still be open — ViaCyte Inc. (latest filing Apr 22, 2021) · No amendment in the last 12 months on an offering that may still be open — PAIGE.AI, Inc. (latest filing Jan 27, 2021) · No amendment in the last 12 months on an offering that may still be open — ImmPACT Bio USA Inc. (latest filing Aug 5, 2020) · and 17 more

What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.

Form D · Mar 17, 2023 ↗PAIGE.AI, Inc. — PartnerFacts page ↗Form D · Dec 29, 2022 ↗SonoThera, Inc. — PartnerFacts page ↗
Sources
Worth asking · Jul 22, 2020 – Nov 23, 2021

Asish Xavier is no longer listed on the Nov 23, 2021 amendment — Magnolia Neurosciences Corp

Asish Xavier appears on the Jul 22, 2020 Form D (director) but not on the Nov 23, 2021 Form D/A for the same offering.

What this means People leave, and the issuer must list only current officers, directors and promoters. It is still worth asking why this person left and who replaced them.

Form D · Jul 22, 2020 ↗Form D/A · Nov 23, 2021 ↗Asish Xavier — PartnerFacts page ↗Magnolia Neurosciences Corp — PartnerFacts page ↗
Sources
Worth asking · Jan 6, 2016 – Jan 4, 2017

Asish Xavier is no longer listed on the Jan 4, 2017 amendment — Petra Pharma Corp

Asish Xavier appears on the Jan 6, 2016 Form D (director) but not on the Jan 4, 2017 Form D/A for the same offering.

What this means People leave, and the issuer must list only current officers, directors and promoters. It is still worth asking why this person left and who replaced them.

Form D · Jan 6, 2016 ↗Form D/A · Jan 4, 2017 ↗Asish Xavier — PartnerFacts page ↗Petra Pharma Corp — PartnerFacts page ↗
Sources
Note · Dec 6, 2010 – Nov 23, 2021

12 offerings changed their target amount between filings

Offering amount changed between filings — Magnolia Neurosciences Corp · Offering amount changed between filings — Rodeo Therapeutics Corp · Offering amount changed between filings — Proniras Corp · Offering amount changed between filings — Rodeo Therapeutics Corp · Offering amount changed between filings — ESCAPE Bio, Inc. · and 7 more

What this means Targets change as deals grow or shrink. Ask whether later money has the same terms.

Form D (earlier) · Jul 22, 2020 ↗Form D/A (later) · Nov 23, 2021 ↗Magnolia Neurosciences Corp — PartnerFacts page ↗Form D/A (earlier) · Mar 29, 2019 ↗
Sources
Note · Jan 5, 2010 – Dec 6, 2010

Asish Xavier is written 2 different ways on the filings

listed as "Asish Xavier" on 45 filings (from Jan 5, 2010), and "Asish K Xavier" on 7 filings (from Dec 6, 2010).

What this means Same person, written differently — a middle name or suffix left off, or spelled another way. It is normal, but check that the full legal name matches your subscription documents.

Form D · Jan 5, 2010 ↗Form D/A · Dec 6, 2010 ↗Asish Xavier — PartnerFacts page ↗
Sources
Note · Aug 31, 2015 – Oct 11, 2018

Industry group changed between filings — ESCAPE Bio, Inc.

"Other Health Care" (Aug 31, 2015 to Jun 2, 2017); then "Biotechnology" (Oct 11, 2018 to Sep 28, 2020).

What this means The issuer described its business differently on different forms. Often it is just a different box ticked; sometimes the deal itself changed. Ask which business your money is in.

Form D · Aug 31, 2015 ↗Form D/A · Oct 11, 2018 ↗ESCAPE Bio, Inc. — PartnerFacts page ↗
Sources
Note · Sep 26, 2011 – Apr 1, 2013

Industry group changed between filings — AQUINOX PHARMACEUTICALS (USA) INC

"Pharmaceuticals" (Sep 26, 2011); then "Other" (Apr 1, 2013).

What this means The issuer described its business differently on different forms. Often it is just a different box ticked; sometimes the deal itself changed. Ask which business your money is in.

Form D · Sep 26, 2011 ↗Form D · Apr 1, 2013 ↗AQUINOX PHARMACEUTICALS (USA) INC — PartnerFacts page ↗
Sources
Note · Aug 31, 2015

Formed in 2020 per the latest filing, but activity is dated 2015 — ESCAPE Bio, Inc.

The issuer's latest filing says it was formed in 2020. The Aug 31, 2015 filing says the first sale was Aug 19, 2015 — before that year.

What this means A company cannot sell before it exists, so one of the two dates is likely a typo on the form. Ask the sponsor for the formation document.

Form D · Aug 31, 2015 ↗ESCAPE Bio, Inc. — PartnerFacts page ↗
Sources
Note · Jun 18, 2012 – Sep 28, 2020

4 address changes between filings

Address moved from San Francisco, CA to South San Francisco, CA — ESCAPE Bio, Inc. · Address moved from South San Francisco, CA to San Francisco, CA — ESCAPE Bio, Inc. · Address moved from San Francisco, CA to South San Francisco, CA — ESCAPE Bio, Inc. · Address moved from Durham, NC to Malvern, PA — PhaseBio Pharmaceuticals Inc

What this means Businesses move. If you were told one city and the forms say another, ask which is current.

Form D · Jul 29, 2019 ↗Form D · Sep 28, 2020 ↗ESCAPE Bio, Inc. — PartnerFacts page ↗Form D/A · Oct 11, 2018 ↗
Sources
Note · Jan 5, 2010 – Jun 11, 2024

Asish Xavier is listed with 7 different address states: NJ, CA, A1, MA, PA, NY, WA

NJ on 9 filings (Jan 5, 2010 to Aug 5, 2020); CA on 21 filings (Aug 18, 2011 to Jun 11, 2024); British Columbia, Canada (as filed: A1) on 2 filings (Sep 26, 2011 to Apr 1, 2013); MA on 3 filings (Oct 11, 2012 to Jul 2, 2013); PA on 3 filings (Mar 12, 2015 to Jan 31, 2017); NY on 7 filings (Jan 4, 2016 to Mar 17, 2023); WA on 7 filings (Aug 2, 2017 to Apr 2, 2020).

What this means The address on a Form D is usually the company's, not the person's home, so this often just reflects different companies. It can also mean a move. Nothing wrong by itself.

Form D · Jan 5, 2010 ↗Form D · Aug 18, 2011 ↗Form D · Sep 26, 2011 ↗Form D · Oct 11, 2012 ↗
Sources
What is compared

What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. We compared the newest 50 of 66 filings (work cap); older filings are not covered here. As of Oct 24, 2026.

5. Money to insiders

3 of 52 offerings report sales commissions totalling $5,651,800; 0 report finder's fees; 1 reports proceeds to related persons totalling $900,000. (includes amounts the issuer reported as estimates)

Offering (latest filing)Sales commissionsFinder's feesTo insidersPaid to sell itSource
Jun 11, 2024 D
Bright Peak Therapeutics, Inc.
File 021-515688
$0$0$0None listed on this filingEDGAR ↗
Mar 17, 2023 D
PAIGE.AI, Inc.
File 021-476128
$0$0$0None listed on this filingEDGAR ↗
Dec 29, 2022 D
SonoThera, Inc.
File 021-469166
$0$0$0None listed on this filingEDGAR ↗
Apr 22, 2021 D
ViaCyte Inc.
File 021-396782
$0$0$0None listed on this filingEDGAR ↗
Jan 27, 2021 D
PAIGE.AI, Inc.
File 021-387450
$0$0$0None listed on this filingEDGAR ↗
Sep 28, 2020 D
ESCAPE Bio, Inc.
File 021-376482
$0$0$0None listed on this filingEDGAR ↗
Aug 5, 2020 D
ImmPACT Bio USA Inc.
File 021-372570
$0$0$0None listed on this filingEDGAR ↗
Jul 22, 2020 D
Magnolia Neurosciences Corp
File 021-371555
$0$0$0None listed on this filingEDGAR ↗
Apr 2, 2020 D/A
Rodeo Therapeutics Corp
File 021-327473
$0$0$0None listed on this filingEDGAR ↗
Apr 2, 2020 D
ViaCyte Inc.
File 021-364188
$0$0$0None listed on this filingEDGAR ↗
Oct 9, 2019 D
Adicet Bio, Inc.
File 021-350688
$2,500,000$0$0Bruce Roberts BrokerCheck CRD 2359901 ↗
via Beech Hill Securities, Inc. (CRD 24771 ↗)

Byung-Chan (Ted) Moon BrokerCheck CRD 4914744 ↗
via Beech Hill Securities, Inc. (CRD 24771 ↗)

Yarone Breski BrokerCheck CRD 5785868 ↗
via Beech Hill Securities, Inc. (CRD 24771 ↗)
EDGAR ↗
Jul 29, 2019 D
ESCAPE Bio, Inc.
File 021-345261
$0$0$0None listed on this filingEDGAR ↗
Jul 11, 2019 D/A
Proniras Corp
File 021-294038
$0$0$0None listed on this filingEDGAR ↗
Dec 3, 2018 D
ViaCyte Inc.
File 021-327013
$2,743,800 (est.)$0$0Raymond James & Associates, Inc. BrokerCheck CRD 705 ↗EDGAR ↗
Oct 11, 2018 D/A
ESCAPE Bio, Inc.
File 021-246718
$0$0$0 (est.)None listed on this filingEDGAR ↗
Aug 24, 2018 D/A
ApoGen Biotechnologies, Inc.
File 021-275911
$0$0$0None listed on this filingEDGAR ↗
Aug 17, 2018 D
Magnolia Neurosciences Corp
File 021-319505
$0$0$0None listed on this filingEDGAR ↗
Aug 2, 2017 D
Rodeo Therapeutics Corp
File 021-291967
$0$0$0None listed on this filingEDGAR ↗
Jan 31, 2017 D
PhaseBio Pharmaceuticals Inc
File 021-279697
$0$0$0None listed on this filingEDGAR ↗
Jan 4, 2017 D/A
Lodo Therapeutics Corp
File 021-254438
$0$0$0None listed on this filingEDGAR ↗
Jan 6, 2016 D
Petra Pharma Corp
File 021-254662
$0$0$0None listed on this filingEDGAR ↗
Jul 21, 2015 D/A
PhaseBio Pharmaceuticals Inc
File 021-235733
$0$0$900,000 (est.)None listed on this filingEDGAR ↗
Jul 13, 2015 D/A
CATALYST BIOSCIENCES INC
File 021-241558
$0$0$0None listed on this filingEDGAR ↗
Feb 3, 2015 D
CATALYST BIOSCIENCES INC
File 021-233381
$0$0$0None listed on this filingEDGAR ↗
Apr 23, 2014 D
CATALYST BIOSCIENCES INC
File 021-216115
$0$0$0None listed on this filingEDGAR ↗
Aug 20, 2013 D
CATALYST BIOSCIENCES INC
File 021-201639
$0$0$0None listed on this filingEDGAR ↗
Jul 19, 2013 D
ViaCyte Inc.
File 021-199943
$0$0$0None listed on this filingEDGAR ↗
Jul 2, 2013 D/A
GENOCEA BIOSCIENCES, INC.
File 021-185355
$0$0$0None listed on this filingEDGAR ↗
Jun 11, 2013 D
Protagonist Therapeutics, Inc
File 021-197788
$0$0$0
Other than the payment of salaries and other compensation and benefits, no officer, director, or promoter will receive any payments from the proceeds of this offering.
None listed on this filingEDGAR ↗
Apr 1, 2013 D
AQUINOX PHARMACEUTICALS (USA) INC
File 021-194308
$0$0$0None listed on this filingEDGAR ↗
Jan 3, 2013 D
Aldeyra Therapeutics, Inc.
File 021-189330
$0$0$0None listed on this filingEDGAR ↗
Sep 25, 2012 D
CATALYST BIOSCIENCES INC
File 021-184613
$0$0$0None listed on this filingEDGAR ↗
Jun 18, 2012 D/A
PhaseBio Pharmaceuticals Inc
File 021-40668
$0$0$0
Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.
None listed on this filingEDGAR ↗
Jan 31, 2012 D
ISCIENCE INTERVENTIONAL CORP
File 021-172696
$0$0$0None listed on this filingEDGAR ↗
Dec 22, 2011 D
Eiger BioPharmaceuticals, Inc.
File 021-170592
$0$0$0None listed on this filingEDGAR ↗
Nov 16, 2011 D
Eiger BioPharmaceuticals, Inc.
File 021-168810
$0$0$0None listed on this filingEDGAR ↗
Oct 28, 2011 D
Eiger BioPharmaceuticals, Inc.
File 021-167978
$0$0$0None listed on this filingEDGAR ↗
Sep 26, 2011 D
AQUINOX PHARMACEUTICALS (USA) INC
File 021-166388
$0$0$0None listed on this filingEDGAR ↗
Sep 1, 2011 D
Eiger BioPharmaceuticals, Inc.
File 021-165275
$0$0$0None listed on this filingEDGAR ↗
Aug 18, 2011 D
ISCIENCE INTERVENTIONAL CORP
File 021-164648
$0$0$0None listed on this filingEDGAR ↗
Jul 12, 2011 D
Eiger BioPharmaceuticals, Inc.
File 021-162710
$0$0$0None listed on this filingEDGAR ↗
May 17, 2011 D
ISCIENCE INTERVENTIONAL CORP
File 021-159929
$0$0$0None listed on this filingEDGAR ↗
Feb 11, 2011 D
AQUINOX PHARMACEUTICALS INC
File 021-155187
$0$0$0None listed on this filingEDGAR ↗
Feb 11, 2011 D
AQUINOX PHARMACEUTICALS (USA) INC
File 021-155188
$0$0$0None listed on this filingEDGAR ↗
Oct 28, 2010 D
Eiger BioPharmaceuticals, Inc.
File 021-149731
$0$0$0None listed on this filingEDGAR ↗
Sep 21, 2010 D/A
ISCIENCE INTERVENTIONAL CORP
File 021-146206
$0$0$0None listed on this filingEDGAR ↗
Jun 25, 2010 D
AQUINOX PHARMACEUTICALS (USA) INC
File 021-144021
$0$0$0None listed on this filingEDGAR ↗
Jun 25, 2010 D
AQUINOX PHARMACEUTICALS INC
File 021-144022
$0$0$0None listed on this filingEDGAR ↗
Apr 16, 2010 D
AQUINOX PHARMACEUTICALS INC
File 021-140721
$0$0$0None listed on this filingEDGAR ↗
Apr 15, 2010 D
AQUINOX PHARMACEUTICALS (USA) INC
File 021-140699
$0$0$0None listed on this filingEDGAR ↗
Dec 17, 2009 D
Eiger BioPharmaceuticals, Inc.
File 021-69966
$0$0$0None listed on this filingEDGAR ↗
Dec 8, 2008 D
CATALYST BIOSCIENCES INC
File 021-60286
$408,000$0$0Seaview Securities LLC BrokerCheck CRD 126180 ↗EDGAR ↗
How this is counted

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Counted across every filing this person is listed on (latest filing per offering, per issuer).

Deals 22

Every issuer that named Asish Xavier on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.

BP
Other

Bright Peak Therapeutics, Inc.

Del Mar, CA · Jun 11, 2024
  • Jun 11, 2024 · D · $89,999,991 sold of $89,999,991 · 21 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $106.5M from 21 investors (100% of the $90M target) as of the latest filing. Asish is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other / 506(b) (18,678 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

PA
Other Health Care

PAIGE.AI, Inc.

New York, NY · Jan 27, 2021 → Mar 17, 2023 · 2 filings
  • Mar 17, 2023 · D · $19,499,894 sold of $38,999,891 · 3 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 27, 2021 · D · $55,000,016 sold of $100,000,000 · 3 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $71M from 26 investors (100% of the $39M target) as of the latest filing. Asish is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

S
Biotechnology

SonoThera, Inc.

South San Francisco, CA · Dec 29, 2022
  • Dec 29, 2022 · D · $30,375,000 sold of $60,750,000 · 12 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $125.5M from 22 investors (100% of the $60.8M target) as of the latest filing. Asish is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

V
Biotechnology

ViaCyte Inc.

San Diego, CA · Jul 19, 2013 → Apr 22, 2021 · 4 filings
  • Apr 22, 2021 · D · $53,931,166 sold of $58,506,166 · 22 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 2, 2020 · D · $32,645,780 sold of $36,018,634 · 17 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 3, 2018 · D · $35,833,603 sold of $90,021,103 · 9 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 19, 2013 · D · $12,150,824 sold of $27,175,642 · 55 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $53.9M from 55 investors (92% of the $58.5M target) as of the latest filing. Asish is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

EB
Biotechnology

ESCAPE Bio, Inc.

South San Francisco, CA · Aug 31, 2015 → Sep 28, 2020 · 5 filings
  • Sep 28, 2020 · D · $73,000,000 sold of $73,000,000 · 29 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 29, 2019 · D · $31,073,380 sold of $35,000,000 · 22 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 11, 2018 · D/A · $63,002,700 sold of $63,002,700 · 31 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 2, 2017 · D/A · $46,002,700 sold of $63,000,000 · 32 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 31, 2015 · D · $20,002,700 sold of $55,002,700 · 6 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $73M from 32 investors (100% of the $73M target) as of the latest filing. Asish is listed as director on 5 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

IB
Biotechnology

ImmPACT Bio USA Inc.

West Hills, CA · Aug 5, 2020
  • Aug 5, 2020 · D · $3,750,000 sold of $5,500,000 · 17 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $139.9M from 17 investors (100% of the $5.5M target) as of the latest filing. Asish is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

MN
Biotechnology

Magnolia Neurosciences Corp

New York, NY · Aug 17, 2018 → Jul 22, 2020 · 2 filings
  • Jul 22, 2020 · D · $5,000,000 sold of $17,909,091 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 17, 2018 · D · $8,000,000 sold of $13,090,909 · 11 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $18.4M from 11 investors (100% of the $17.9M target) as of the latest filing. Asish is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

RT
Biotechnology

Rodeo Therapeutics Corp

Seattle, WA · Aug 2, 2017 → Apr 2, 2020 · 4 filings
  • Apr 2, 2020 · D/A · $8,950,000 sold of $8,950,000 · 9 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 29, 2019 · D/A · $7,949,999 sold of $7,949,999 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 10, 2018 · D · $3,685,714 sold of $4,571,475 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 2, 2017 · D · $5,354,000 sold of $5,900,000 · 8 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $8.95M from 9 investors (100% of the $8.95M target) as of the latest filing. Asish is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AB
Biotechnology

Adicet Bio, Inc.

Menlo Park, CA · Oct 9, 2019
  • Oct 9, 2019 · D · $80,000,000 sold of $80,000,000 · 18 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $80M from 18 investors (100% of the $80M target) as of the latest filing. Asish is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

PC
Biotechnology

Proniras Corp

Seattle, WA · Sep 5, 2017 → Jul 11, 2019 · 2 filings
  • Jul 11, 2019 · D/A · $4,300,000 sold of $4,300,000 · 7 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 5, 2017 · D · $2,800,000 sold of $2,800,000 · 7 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $6.93M from 10 investors (100% of the $4.3M target) as of the latest filing. Asish is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AB
Biotechnology

ApoGen Biotechnologies, Inc.

Seattle, WA · Dec 8, 2016 → Aug 24, 2018 · 2 filings
  • Aug 24, 2018 · D/A · $7,565,892 sold of $7,565,892 · 24 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 8, 2016 · D · $3,815,892 sold of $7,315,892 · 23 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $7.57M from 24 investors (100% of the $7.57M target) as of the latest filing. Asish is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

PP
Biotechnology

PhaseBio Pharmaceuticals Inc

Malvern, PA · Jan 5, 2010 → Jan 31, 2017 · 6 filings
  • Jan 31, 2017 · D · $6,615,000 sold of $7,875,000 · 9 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 21, 2015 · D/A · $21,000,000 sold of $42,000,000 · 9 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 12, 2015 · D · $20,000,000 sold of $40,000,000 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 18, 2012 · D/A · $48,524,067 sold of $48,524,067 · 17 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 6, 2010 · D/A · $25,300,001 sold of $25,300,001 · 12 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 5, 2010 · D · $10,120,000 sold of $25,300,001 · 12 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $48.5M from 20 investors (100% of the $7.88M target) as of the latest filing. Asish is listed as director on 6 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

LT
Biotechnology

Lodo Therapeutics Corp

New York, NY · Jan 4, 2016 → Jan 4, 2017 · 2 filings
  • Jan 4, 2017 · D/A · $19,867,600 sold of $19,867,600 · 13 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 4, 2016 · D · $3,517,600 sold of $3,658,304 · 13 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $19.9M from 13 investors (100% of the $19.9M target) as of the latest filing. Asish is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

PP
Biotechnology

Petra Pharma Corp

New York, NY · Jan 6, 2016
  • Jan 6, 2016 · D · $9,992,200 sold of $10,410,478 · 12 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $31.2M from 13 investors (100% of the $10.4M target) as of the latest filing. Asish is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

CB
Biotechnology

CATALYST BIOSCIENCES INC

South San Fransicso, CA · Dec 8, 2008 → Jul 13, 2015 · 7 filings
  • Jul 13, 2015 · D/A · $1,890,938 sold of $2,000,000 · 10 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 11, 2015 · D · $1,000,000 sold of $1,000,000 · 10 investors · min. No minimum reported · role: Director EDGAR ↗
  • Feb 3, 2015 · D · $3,224,993 sold of $5,000,000 · 11 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 23, 2014 · D · $5,009,841 sold of $5,009,841 · 18 investors · min. $3,000 · role: Director EDGAR ↗
  • Aug 20, 2013 · D · $400,004 sold of $800,008 · 11 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 25, 2012 · D · $13,407,658 sold of $18,593,361 · 21 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 8, 2008 · D · $40,399,998 sold of $40,399,998 · 10 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $40.4M from 21 investors (100% of the $2M target) as of the latest filing. Asish is listed as director on 7 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

GB
Biotechnology

GENOCEA BIOSCIENCES, INC.

Cambridge, MA · Oct 11, 2012 → Jul 2, 2013 · 2 filings
  • Jul 2, 2013 · D/A · $30,500,000 sold of $30,500,000 · 21 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 11, 2012 · D · $15,250,000 sold of $30,500,000 · 21 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $75.5M from 21 investors (100% of the $30.5M target) as of the latest filing. Asish is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

PT
Biotechnology

Protagonist Therapeutics, Inc

Milpitas, CA · Jun 11, 2013
  • Jun 11, 2013 · D · $7,000,000 sold of $18,040,000 · 4 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $17.5M from 9 investors (97% of the $18M target) as of the latest filing. Asish is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

AP
Other · group: Aquinox Pharmaceuticals

AQUINOX PHARMACEUTICALS (USA) INC

Richmond, British Columbia, Canada (as filed: A1) · Apr 15, 2010 → Apr 1, 2013 · 5 filings
  • Apr 1, 2013 · D · $13,999,975 sold of $20,999,962 · 7 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 26, 2011 · D · $3,536,035 sold of $3,536,035 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Feb 11, 2011 · D · $4,724,298 sold of $4,724,298 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 25, 2010 · D · $3,531,483 sold of $3,531,483 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 15, 2010 · D · $4,827,549 sold of $6,227,549 · 5 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $14M from 7 investors (67% of the $21M target) as of the latest filing. Asish is listed as director on 5 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

AT
Biotechnology

Aldeyra Therapeutics, Inc.

Lexington, MA · Jan 3, 2013
  • Jan 3, 2013 · D · $4,793,666 sold of $8,787,906 · 2 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $10M from 37 investors (100% of the $8.79M target) as of the latest filing. Asish is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

II
Other Health Care

ISCIENCE INTERVENTIONAL CORP

Menlo Park, CA · Aug 11, 2010 → Jan 31, 2012 · 5 filings
  • Jan 31, 2012 · D · $2,759,185 sold of $5,000,000 · 12 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 18, 2011 · D · $3,000,000 sold of $3,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 17, 2011 · D · $5,335,545 sold of $6,000,000 · 12 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 21, 2010 · D/A · $5,087,965 sold of $10,000,000 · 18 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 11, 2010 · D · $3,601,069 sold of $3,601,069 · 15 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $20.5M from 18 investors (100% of the $5M target) as of the latest filing. Asish is listed as director on 5 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

EB
Biotechnology · group: Eiger Biopharmaceuticals

Eiger BioPharmaceuticals, Inc.

Palo Alto, CA · Sep 10, 2009 → Dec 22, 2011 · 8 filings
  • Dec 22, 2011 · D · $500,000 sold of $500,000 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 16, 2011 · D · $330,000 sold of $500,000 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 28, 2011 · D · $200,000 sold of $200,000 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 1, 2011 · D · $250,000 sold of $250,000 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 12, 2011 · D · $400,000 sold of $400,000 · 2 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 28, 2010 · D · $2,500,000 sold of $4,000,000 · 7 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 17, 2009 · D · $3,500,000 sold of $6,500,000 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 10, 2009 · D/A · $21,800,002 sold of $24,631,114 · 6 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $21.8M from 24 investors (100% of the $500K target) as of the latest filing. Asish is listed as director on 8 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

AP
Pharmaceuticals · group: Aquinox Pharmaceuticals

AQUINOX PHARMACEUTICALS INC

Richmond, British Columbia, Canada (as filed: A1) · Apr 16, 2010 → Feb 11, 2011 · 3 filings
  • Feb 11, 2011 · D · $9 sold of $9 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 25, 2010 · D · $6 sold of $6 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 16, 2010 · D · $9 sold of $9 · 5 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $26 from 7 investors (100% of the $9 target) as of the latest filing. Asish is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

People around Asish 40

Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET. Showing the 40 with the most shared filings.

TL
No photo found yet (own website and image search run after this page is viewed)
Person

Thong Le

Executive Officer, Director, Promoter · 13 shared filings (6 issuers) · also on 8 other issuers

Thong Le is on 14 issuers in total — a repeat sponsor. Their page lists every one.

SG
No photo found yet (own website and image search run after this page is viewed)
Person

Steve Gillis

Director, Executive Officer, Promoter · 13 shared filings (6 issuers) · also on 9 other issuers

Steve Gillis is on 15 issuers in total — a repeat sponsor. Their page lists every one.

JM
No photo found yet (own website and image search run after this page is viewed)
Person

Joel S. Marcus

Director · 11 shared filings (6 issuers) · also on 12 other issuers

Joel S. Marcus is on 18 issuers in total — a repeat sponsor. Their page lists every one.

DS
No photo found yet (own website and image search run after this page is viewed)
Person

David Schubert

Executive Officer, Promoter · 10 shared filings (6 issuers) · also on 3 other issuers

David Schubert is on 9 issuers in total — a repeat sponsor. Their page lists every one.

RL
No photo found yet (own website and image search run after this page is viewed)
Person

Rebecque Laba

Executive Officer · 8 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Asish Xavier. Their page shows their other deals.

KZ
No photo found yet (own website and image search run after this page is viewed)
Person

Krisztina Zsebo

Executive Officer, Director · 8 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Asish Xavier. Their page shows their other deals.

AS
No photo found yet (own website and image search run after this page is viewed)
Person

Andrew E. Senyei

Director · 8 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Asish Xavier. Their page shows their other deals.

KC
No photo found yet (own website and image search run after this page is viewed)
Person

Kenneth R. Chien

Director · 8 shared filings (1 issuer)

Listed on the same filings as Asish Xavier. Their page shows their other deals.

AE
No photo found yet (own website and image search run after this page is viewed)
Person

Anthony B. Evnin

Director · 8 shared filings (1 issuer)

Listed on the same filings as Asish Xavier. Their page shows their other deals.

KG
No photo found yet (own website and image search run after this page is viewed)
Person

Kenneth Galbraith

Director · 8 shared filings (2 issuers) · also on 3 other issuers

Kenneth Galbraith is on 5 issuers in total — a repeat sponsor. Their page lists every one.

DM
No photo found yet (own website and image search run after this page is viewed)
Person

David J. Main

Executive Officer, Director, Promoter · 8 shared filings (2 issuers) · also on 1 other issuer

Listed on the same filings as Asish Xavier. Their page shows their other deals.

DL
No photo found yet (own website and image search run after this page is viewed)
Person

Daniel Levitt

Director · 8 shared filings (2 issuers)

Listed on the same filings as Asish Xavier. Their page shows their other deals.

NU
No photo found yet (own website and image search run after this page is viewed)
Person

Nassim Usman

Executive Officer, Director · 7 shared filings (1 issuer) · also on 3 other issuers

Listed on the same filings as Asish Xavier. Their page shows their other deals.

JH
No photo found yet (own website and image search run after this page is viewed)
Person

Jeff Himawan

Director · 7 shared filings (1 issuer) · also on 5 other issuers

Jeff Himawan is on 6 issuers in total — a repeat sponsor. Their page lists every one.

LR
No photo found yet (own website and image search run after this page is viewed)
Person

Lindsay Rayle

Executive Officer, Promoter · 7 shared filings (5 issuers) · also on 4 other issuers

Lindsay Rayle is on 9 issuers in total — a repeat sponsor. Their page lists every one.

RC
No photo found yet (own website and image search run after this page is viewed)
Person

Ralph Christoffersen

Director · 7 shared filings (1 issuer) · also on 6 other issuers

Ralph Christoffersen is on 7 issuers in total — a repeat sponsor. Their page lists every one.

AL
No photo found yet (own website and image search run after this page is viewed)
Person

Augustine Lawlor

Director · 7 shared filings (1 issuer) · also on 15 other issuers

Augustine Lawlor is on 16 issuers in total — a repeat sponsor. Their page lists every one.

AC
No photo found yet (own website and image search run after this page is viewed)
Person

Ashutosh Chilkoti

Director, Executive Officer · 6 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Asish Xavier. Their page shows their other deals.

GF
No photo found yet (own website and image search run after this page is viewed)
Person

Guy Fish

Director · 6 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Asish Xavier. Their page shows their other deals.

SM
No photo found yet (own website and image search run after this page is viewed)
Person

Stephen Majlath

Executive Officer · 6 shared filings (2 issuers)

Listed on the same filings as Asish Xavier. Their page shows their other deals.

JS
No photo found yet (own website and image search run after this page is viewed)
Person

James Sullivan

Director · 6 shared filings (4 issuers) · also on 2 other issuers

James Sullivan is on 6 issuers in total — a repeat sponsor. Their page lists every one.

IH
No photo found yet (own website and image search run after this page is viewed)
Person

Ian Howes

Executive Officer · 6 shared filings (3 issuers) · also on 2 other issuers

Ian Howes is on 5 issuers in total — a repeat sponsor. Their page lists every one.

CT
No photo found yet (own website and image search run after this page is viewed)
Person

Clay Thorp

Director · 6 shared filings (1 issuer) · also on 18 other issuers

Clay Thorp is on 19 issuers in total — a repeat sponsor. Their page lists every one.

HS
No photo found yet (own website and image search run after this page is viewed)
Person

Harold Selick

Director · 6 shared filings (2 issuers) · also on 2 other issuers

Listed on the same filings as Asish Xavier. Their page shows their other deals.

PT
No photo found yet (own website and image search run after this page is viewed)
Person

Peter A. Thompson

Director · 5 shared filings (1 issuer) · also on 28 other issuers

Peter A. Thompson is on 29 issuers in total — a repeat sponsor. Their page lists every one.

MN
No photo found yet (own website and image search run after this page is viewed)
Person

Michael Nash

Director, Executive Officer · 5 shared filings (1 issuer) · also on 48 other issuers

Michael Nash is on 49 issuers in total — a repeat sponsor. Their page lists every one.

WJ
No photo found yet (own website and image search run after this page is viewed)
Person

Wilfred Jaeger

Director · 5 shared filings (1 issuer) · also on 3 other issuers

Listed on the same filings as Asish Xavier. Their page shows their other deals.

JB
No photo found yet (own website and image search run after this page is viewed)
Person

James Barrett

Director · 5 shared filings (1 issuer) · also on 6 other issuers

James Barrett is on 7 issuers in total — a repeat sponsor. Their page lists every one.

JR
No photo found yet (own website and image search run after this page is viewed)
Person

Josh Resnick

Director · 5 shared filings (1 issuer) · also on 3 other issuers

Listed on the same filings as Asish Xavier. Their page shows their other deals.

KJ
No photo found yet (own website and image search run after this page is viewed)
Person

Kristine Johnson

Director · 5 shared filings (1 issuer)

Listed on the same filings as Asish Xavier. Their page shows their other deals.

GC
No photo found yet (own website and image search run after this page is viewed)
Person

Graham Crooke

Director · 5 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Asish Xavier. Their page shows their other deals.

JK
No photo found yet (own website and image search run after this page is viewed)
Person

Justin Klein

Director · 5 shared filings (1 issuer) · also on 3 other issuers

Listed on the same filings as Asish Xavier. Their page shows their other deals.

RI
No photo found yet (own website and image search run after this page is viewed)
Person

Robert A. Ingram

Director · 5 shared filings (1 issuer) · also on 8 other issuers

Robert A. Ingram is on 9 issuers in total — a repeat sponsor. Their page lists every one.

PM
No photo found yet (own website and image search run after this page is viewed)
Person

Peter Moldt

Director · 5 shared filings (1 issuer) · also on 10 other issuers

Peter Moldt is on 11 issuers in total — a repeat sponsor. Their page lists every one.

ME
No photo found yet (own website and image search run after this page is viewed)
Person

M. Johnston Erwin

Director · 5 shared filings (3 issuers)

Listed on the same filings as Asish Xavier. Their page shows their other deals.

MP
No photo found yet (own website and image search run after this page is viewed)
Person

Michael Powell

Director · 5 shared filings (1 issuer) · also on 8 other issuers

Michael Powell is on 9 issuers in total — a repeat sponsor. Their page lists every one.

RW
No photo found yet (own website and image search run after this page is viewed)
Person

R. Sanders Williams

Director · 5 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Asish Xavier. Their page shows their other deals.

KM
No photo found yet (own website and image search run after this page is viewed)
Person

Kendall Mohler

Executive Officer · 4 shared filings (2 issuers) · also on 3 other issuers

Kendall Mohler is on 5 issuers in total — a repeat sponsor. Their page lists every one.

FM
No photo found yet (own website and image search run after this page is viewed)
Person

Fred A. Middleton

Director · 4 shared filings (1 issuer) · also on 14 other issuers

Fred A. Middleton is on 15 issuers in total — a repeat sponsor. Their page lists every one.

AS
No photo found yet (own website and image search run after this page is viewed)
Person

Anne Sandan

Executive Officer · 4 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Asish Xavier. Their page shows their other deals.

The team behind the deals

AP
Sponsor group

Aquinox Pharmaceuticals

2 issuers · 10 filings · $14M reported sold · 2010–2013

One team, 2 deal companies. Asish Xavier is listed on 2 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Asish Xavier.

EB
Sponsor group

Eiger Biopharmaceuticals

2 issuers · 22 filings · $9M reported sold · 2009–2016

One team, 2 deal companies. Asish Xavier is listed on 1 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Asish Xavier.

Same business address

46 other issuers file from the same address

A shared address can mean the same team, a shared office building or a registered agent. It is a lead, not a conclusion.

Registrations and other filings

Business registration (state registry / Secretary of State)

Individuals are not matched to business registrations — registries list companies, and a name alone is not enough to tie a person to one. Officers and managers appear by name inside each matched company's record on the issuer pages. Registries searched: AL (Alabama Secretary of State — Business Entity Records (arc-sos.state.al.us), searched by issuer name, data as of Oct 24, 2026); CO (Colorado Secretary of State — Business Entities in Colorado (data.colorado.gov), data as of Oct 23, 2026); CT (Connecticut Secretary of the State — Business Registry (data.ct.gov), data as of Oct 24, 2026); FL (Florida Department of State, Division of Corporations — quarterly corporate data file (Sunbiz), data as of Oct 7, 2026); KY (Kentucky Secretary of State — Business Entity Search (sosbes.sos.ky.gov), searched by issuer name, data as of Oct 24, 2026); NY (New York Department of State — Corporations and Other Entities (data.ny.gov: All Filings + Active Corporations), data as of Oct 20, 2026); OR (Oregon Secretary of State — Active Businesses, All (data.oregon.gov), data as of Oct 20, 2026); PA (Pennsylvania Department of State — Registered Businesses, Current (data.pa.gov), data as of Oct 6, 2026); TX (Texas Comptroller — Active Franchise Taxpayers incl. Secretary of State file data (data.texas.gov), data as of Oct 24, 2026). Registries of other states have not been searched: many publish no bulk file and require a CAPTCHA or bot challenge on their search page, which we do not bypass (Delaware, for example, offers no public bulk file).

Adviser registration (Form ADV)

None of the 22 issuers this person is listed on appears in Form ADV (searched 24,962 advisers as of Oct 2, 2026). A person is never an adviser firm; Form ADV is checked for the issuers and the management companies they are listed with.

Other offering types (Regulation A and Regulation Crowdfunding)

Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.

Property records none — individuals are not matched

Property records are matched to companies only, never to individuals, so none are matched to Asish Xavier by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 22 issuers this person is listed on — nothing matched.

Public profiles and social

Websites and social links of the issuers Asish Xavier is listed on: none on file. No website or social profile named in Bright Peak Therapeutics, Inc.'s SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #97,446 of 374,652 in line (1,386 issuers searched so far). One-tap searches: Look further ↓

Look further

One-tap searches on sites we do not index ourselves, with the name pre-filled (Del Mar, CA). Each opens in a new tab; what you find there is not verified by PartnerFacts.

Social and web

LinkedIn people search ↗Instagram ↗X (Twitter) ↗Facebook ↗YouTube ↗Google ↗Google Images ↗Google News ↗Meta Ad Library ↗

Courts

CourtListener / RECAP (federal) ↗PACER case locator (federal, login) ↗California — find the county court ↗Los Angeles Superior Court case search ↗New Jersey state courts — find the court ↗Massachusetts MassCourts ↗Pennsylvania UJS portal case search ↗New York WebCivil Supreme ↗Washington Courts case search (dw.courts.wa.gov) ↗

Securities regulators

SEC EDGAR full-text search ↗SEC action look-up ↗FINRA BrokerCheck ↗SEC IAPD adviser search ↗

Business registries

California Secretary of State business search ↗New Jersey Secretary of State business search ↗Massachusetts Secretary of State business search ↗Pennsylvania Secretary of State business search ↗New York Secretary of State business search ↗Washington Secretary of State business search ↗OpenCorporates ↗

Change history

No corrections have been requested for this page.

Every fact links to its public-record source. Plain-English notes next to a fact are our reading of that fact, not a rating. Request a correction · Facts policy

Request a correction

Free. Logged with status: received → under review → fixed / confirmed with source.

Add a response

If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.

Monitor this person

Members get an email when Asish Xavier appears on a new Form D, or when a court case or SEC action is matched to them. See plans →